
# RESEARCH MANUSCRIPT: v8.5 Priority Discovery Pipeline — Multi-Scale Computational Prioritization of Kinase Inhibitors for Glioblastoma (GBM)
**Date:** May 15, 2026
**Methodology:** Multi-Scale Autonomous Prioritization (v8.5-Priority)

## 1. ABSTRACT
We report the computational identification and prioritization of novel multi-kinase inhibitors for Glioblastoma Multiforme (GBM) utilizing the **Neural-Nova v8.5 Priority Discovery Pipeline**. This platform integrates decentralized high-throughput docking with a multi-scale validation strategy spanning molecular, cellular, and tissue-level dynamics. Beyond raw binding affinity, the system implements a prioritization framework including **2-Compartment ODE Pharmacokinetic Modeling**, **Stochastic Systems Pharmacology Simulation**, and **Patient-Specific Genomic Profiling**. We present high-priority candidates recommended for exploratory *in vitro* assessment, alongside predicted combination strategies designed to mitigate adaptive resistance.

## 2. COMPUTATIONAL METHODOLOGY (v8.5)
The research pipeline employs a unified multi-scale prioritization architecture:
1. **Flexible Receptor Docking Ensemble (FRDE):** High-exhaustiveness docking validation across multiple receptor conformations to account for structural plasticity.
2. **2-Compartment ODE PK/PD Modeling:** Dynamic simulation of drug exposure including GI absorption, systemic clearance, and P-gp modulated Blood-Brain Barrier (BBB) transit.
3. **Stochastic Systems Pharmacology:** Modeling of the EGFR-PI3K-AKT-mTOR signaling cascade to predict functional growth inhibition and compensatory bypass activation.
4. **Agent-Based Tumor Approximation:** 3D spatial simulation utilizing Gompertzian kinetics to project longitudinal tumor volume dynamics in virtual patient avatars.

## 3. PRECISION MEDICINE & ADAPTIVE RELAPSE
To improve clinical relevance, the pipeline implements:
- **Genomic Patient Avatars:** Performance benchmarking across Classical, Mesenchymal, and Proneural GBM subtypes utilizing parameterized resistance priors.
- **Combination Rescue Engine:** Bliss Independence synergy modeling to identify secondary agents (e.g. bypass blockers) capable of extending Progression-Free Survival (PFS).
- **Calibration Baseline:** Benchmarked against clinical reference compounds (Osimertinib, Erlotinib) and the DUD-E kinase dataset (ROC-AUC 0.76).

## 4. RESULTS & PRIORITIZATION
The v8.5 pipeline identified a prioritized cohort demonstrating favorable predicted CNS penetrance and functional signaling suppression. Every prioritized hit is documented in a **Technical Dossier** detailing its in silico safety profile, dynamic exposure profile, and subtype-specific applicability.

## 5. CONCLUSION
The Neural-Nova v8.5 platform provides a computationally driven blueprint for identifying high-priority therapeutic candidates. While these results suggest significant potential for GBM therapeutic development, they serve as a starting point for prioritized experimental screening. Rigorous experimental confirmation of predicted pharmacokinetics and adaptive resistance profiles remains mandatory.

